Matching LGS Seizure Types to Treatments Improves Outcomes
A sweeping 2025 review maps which drugs, surgeries, and devices work best for each seizure type in Lennox-Gastaut Syndrome.
Summary
Lennox-Gastaut Syndrome (LGS) is one of the most treatment-resistant epilepsies, marked by multiple seizure types that respond differently to therapies. This 2025 comprehensive review analyzed randomized trials, observational studies, and real-world data through February 2025 to map seizure-type-specific responses. Key findings show corpus callosotomy excels for atonic seizures, while medications like felbamate and lamotrigine favor generalized tonic-clonic seizures. Myoclonic seizures respond best to clonazepam and topiramate, whereas atypical absences benefit from valproate and rufinamide. The ketogenic diet and resective surgery show broad but less characterized efficacy. Emerging tools like deep brain stimulation and responsive neurostimulation show promise. The authors call for a precision, network-based treatment approach guided by individual seizure profiles.
Detailed Summary
Lennox-Gastaut Syndrome is a severe developmental and epileptic encephalopathy affecting children and persisting into adulthood, characterized by multiple drug-resistant seizure types, cognitive impairment, and abnormal EEG patterns. Because patients experience several distinct seizure types simultaneously, clinicians face a uniquely complex treatment challenge — a therapy that helps one seizure type may be ineffective or even worsen another.
This comprehensive 2025 review, conducted by neurologists from the University of Arkansas and Penn State Health, synthesized evidence from randomized controlled trials, observational studies, and real-world data published through February 2025. The aim was to create a seizure-type-specific therapeutic map — moving beyond global seizure reduction as the sole treatment target.
Key findings reveal meaningful differences in treatment response by seizure type. Atonic seizures respond best to corpus callosotomy and vagus nerve stimulation (VNS), with corpus callosotomy showing superior efficacy. Generalized tonic-clonic seizures respond favorably to felbamate, lamotrigine, topiramate, fenfluramine, lacosamide, and perampanel. Myoclonic seizures are better controlled by clonazepam, topiramate, zonisamide, brivaracetam, and perampanel, but respond poorly to neuromodulation. Atypical absence seizures benefit from valproate, topiramate, and rufinamide, but show limited response to brivaracetam and perampanel. The ketogenic diet and resective surgery demonstrate broad cross-seizure efficacy, though seizure-type-specific data remain sparse.
Emerging neuromodulation strategies — including deep brain stimulation and responsive neurostimulation — show early promise particularly for tonic and generalized tonic-clonic seizures, but require further investigation before firm recommendations can be made.
The authors advocate for a precision medicine framework where treatment selection is driven by a patient's predominant seizure types rather than a one-size-fits-all protocol. They also highlight the urgent need for future clinical trials to report seizure-type-specific outcomes and long-term efficacy data to refine this approach.
Key Findings
- Corpus callosotomy is the most effective intervention specifically for atonic seizures in LGS.
- Generalized tonic-clonic seizures respond well to felbamate, lamotrigine, topiramate, and perampanel.
- Myoclonic seizures benefit from clonazepam and brivaracetam but show poor neuromodulation response.
- Atypical absence seizures respond to valproate and rufinamide but not brivaracetam or perampanel.
- Deep brain stimulation and responsive neurostimulation show early promise but need more evidence.
Methodology
This is a comprehensive narrative review synthesizing randomized controlled trials, observational studies, and real-world evidence published through February 2025. No original patient data were collected; conclusions are drawn from aggregated published literature. The review is limited to available published evidence, which varies in quality and seizure-type-specific reporting across studies.
Study Limitations
The review is based only on available published literature, which frequently lacks seizure-type-specific outcome reporting, limiting the granularity of conclusions. Long-term efficacy data across all treatment modalities remain scarce, and the evidence base is heterogeneous in study design and patient populations. Findings may not fully generalize across the wide etiological spectrum of LGS.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: